49 related articles for article (PubMed ID: 38568692)
1. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
ESMO Open; 2023 Dec; 8(6):102033. PubMed ID: 37866031
[TBL] [Abstract][Full Text] [Related]
3. Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer.
Knudsen AM; Modvig MW; Vogsen M; Kodahl AR
Med Oncol; 2024 Mar; 41(5):99. PubMed ID: 38538985
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797792
[TBL] [Abstract][Full Text] [Related]
5. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution.
Gonçalves DS; Migowski A; Costa SCVD; Costa RSD; Senna KMSE; Zimmermann IR
Rev Bras Epidemiol; 2023; 26():e230045. PubMed ID: 37878833
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum to "A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone": [ESMO Open 8 (2023) 102033].
Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
ESMO Open; 2024 Jun; 9(6):103621. PubMed ID: 38870668
[No Abstract] [Full Text] [Related]
8. Erratum: Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
JCO Oncol Pract; 2024 Jun; 20(6):872. PubMed ID: 38507668
[No Abstract] [Full Text] [Related]
9. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
10. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey N; Sandoval A; Mahtani R
Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
[TBL] [Abstract][Full Text] [Related]
11. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
[TBL] [Abstract][Full Text] [Related]
12. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU; Murthy RK; Abramson V; Anders C; Bachelot T; Bedard PL; Borges V; Cameron D; Carey LA; Chien AJ; Curigliano G; DiGiovanna MP; Gelmon K; Hortobagyi G; Hurvitz SA; Krop I; Loi S; Loibl S; Mueller V; Oliveira M; Paplomata E; Pegram M; Slamon D; Zelnak A; Ramos J; Feng W; Winer E
JAMA Oncol; 2023 Feb; 9(2):197-205. PubMed ID: 36454580
[TBL] [Abstract][Full Text] [Related]
13. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
[TBL] [Abstract][Full Text] [Related]
14. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
